Can Decision Analytic Modelling Promote Clinical Translation Of Personalised Medicine Markers For Oncology Drugs?
Funder
National Health and Medical Research Council
Funding Amount
$69,893.00
Summary
Personalised medicine is an approach that has great potential to improve healthcare. There has been limited success to date, however, in utilising proposed tests in the clinical. It is proposed that use of mathematical models early in the development of personalised medicine tests will allow early understanding of the value that the test will have for patients and society. Such insight will help build a strong case to undertake the research required before personalised medicine can be more widel ....Personalised medicine is an approach that has great potential to improve healthcare. There has been limited success to date, however, in utilising proposed tests in the clinical. It is proposed that use of mathematical models early in the development of personalised medicine tests will allow early understanding of the value that the test will have for patients and society. Such insight will help build a strong case to undertake the research required before personalised medicine can be more widely used to improve treatment for cancer.Read moreRead less
Pharmacogenetics Of Methadone Maintenance Treatment
Funder
National Health and Medical Research Council
Funding Amount
$355,564.00
Summary
There is large amount of inter-individual variability in response to methadone use in dependence programmes. Many factors are involved including age, disease and the use of other drugs. Until recently a person's genetic makeup was not amongst these factors. Our study will show how genetic variability that alters the transport or the drug target in the body impacts on a person's drug response and side effects to methadone used to treat opioid dependence.
Kidney transplantation is the only cure for end-stage kidney disease. Although drugs are used to prevent rejection of the new kidney, there is significant inter-individual variability in patients' repsonse. Many factors are involved including age, other diseases and use of other drugs. Individual's genetic make up may also contribute to this variability. This study will show how variability in genes that control drug transport and action affect the risk of rejection and long-term kidney function ....Kidney transplantation is the only cure for end-stage kidney disease. Although drugs are used to prevent rejection of the new kidney, there is significant inter-individual variability in patients' repsonse. Many factors are involved including age, other diseases and use of other drugs. Individual's genetic make up may also contribute to this variability. This study will show how variability in genes that control drug transport and action affect the risk of rejection and long-term kidney function.Read moreRead less
CONTAINMENT OF THE T-CELL RESPONSE TO GLUTEN IN COELIAC DISEASE
Funder
National Health and Medical Research Council
Funding Amount
$324,270.00
Summary
Coeliac disease affects about 1% of Casucasians and West Asians, about 250,000 Australians. Diagnosis of coeliac disease is problematic, less than one fifth of Australians with coeliac disease have been diagnosed, while many more adopt a gluten free diet and strictly avoid foods made from wheat, barley, rye and oats mistakenly thinking that they have coeliac disease. New diagnostics and therapies that are easy to perform and acceptable to patients are badly needed if the public are to benefit fr ....Coeliac disease affects about 1% of Casucasians and West Asians, about 250,000 Australians. Diagnosis of coeliac disease is problematic, less than one fifth of Australians with coeliac disease have been diagnosed, while many more adopt a gluten free diet and strictly avoid foods made from wheat, barley, rye and oats mistakenly thinking that they have coeliac disease. New diagnostics and therapies that are easy to perform and acceptable to patients are badly needed if the public are to benefit from emerging understanding of coeliac disease. It is an unfortunate mistake that the immune system recognizes and reacts to gluten in people with coeliac disease. The immune cells that sense gluten and damage the intestine, T-cells, detect only very specific short fragments (epitopes) of gluten proteins. Understanding which gluten fragments cause coeliac disease would enable new tests to diagnose coeliac disease, design of non-toxic gluten, and may even allow new treatments that could desensitise the immune system to gluten in the same way that desensitisation therapy works for allergy. Understanding of the gluten fragments causing coeliac disease is improving but it is still incomplete. We have developed a simple test that can pin-point the gluten fragments recognized by any individual with coeliac disease. With the help of volunteers with coeliac disease and a library of fragmented gluten proteins, we will be able to map all the regions of gluten in wheat, barley, rye, and oats that stimulate T-cells. We will find the most potent epitopes that could be used in diagnostic tests, food tests, and desensitisation therapy. Studying individuals with coeliac disease when they eat oats, normally a forbidden food for coeliac suffers yet fewer than 1:4 actually react to oats, will define the changes in intestinal tissue following destructive or tolerant responses to this grain and provide a tool to assess future desensitisation therapies for coeliac disease.Read moreRead less
Many recent gene mapping efforts have focused on population based approaches instead of previously used family based approaches. One of the limiting factors with population based approaches is the cost of the technology - each participant must be evaluated (or genotyped) for hundreds of thousands of genetic markers. The cost can be reduced by using an approach which pools individuals together for genotyping, with statistical models used to deal with the problems that this creates.
INTER-ETHNIC DIFFERENCES IN TOLERANCE OF ANTI-CANCER DRUGS
Funder
National Health and Medical Research Council
Funding Amount
$345,894.00
Summary
In 2 previous studies we have shown that Asian cancer patients experience more side-effects than their Caucasian counterparts when treated with the same dose and schedule of treatment. This does not appear to be related to any difference in size. We wish to explain this difference as it may avoid Asian patients receiving overdoses of treatment. Possible causes include dietary and nutritional differences